8-K: 10x Genomics Appoints Alan V. Mateo to Board of Directors

10x Genomics has appointed Alan V. Mateo, a seasoned life sciences executive, to its Board of Directors, effective immediately.

Summary

• 10x Genomics has appointed Alan V. Mateo to its Board of Directors as a Class II director.
• Mr. Mateo's term will expire at the company's 2027 annual meeting of stockholders.
• He previously served as Executive Vice President, Global Sales at Veeva Systems Inc. and held executive roles at Medidata Solutions, Inc.
• Mr. Mateo will receive an annual cash retainer of $55,000.
• He will also receive a one-time grant of restricted stock units valued at $400,000, vesting over three years.
• Additionally, he will receive an annual grant of restricted stock units valued at $215,000, vesting quarterly.
• Mr. Mateo is also eligible for additional cash retainers if he serves on board committees.
• He has entered into the company's standard indemnification agreement.

Sentiment

Score: 7

Explanation: The appointment of a new board member is generally positive, indicating growth and stability. The compensation package is standard and does not raise any concerns.

Positives

• The appointment of Alan V. Mateo brings significant industry experience to the 10x Genomics board.
• Mr. Mateo's background in sales and operations within the life sciences sector is expected to be valuable.
• The compensation package for Mr. Mateo is clearly defined and includes both cash and equity components.

Management Comments

• The Company believes Mr. Mateo is qualified to serve on the Board of Directors because of his senior management experience in the life science industry and his many years of commercial leadership experience.

Industry Context

The appointment of a seasoned executive like Alan V. Mateo reflects a trend in the life sciences industry to strengthen leadership teams with individuals who have a proven track record in commercial operations and sales.

Comparison to Industry Standards

• The compensation package for non-employee directors at 10x Genomics, including cash retainers and stock grants, is generally in line with industry standards for publicly traded companies in the biotechnology and life sciences sectors.
• Companies like Illumina, Thermo Fisher Scientific, and Agilent Technologies also provide similar compensation structures for their non-employee directors, often including a mix of cash and equity-based incentives.
• The vesting schedule for the restricted stock units is also typical, with vesting occurring over a period of several years to align the director's interests with the long-term performance of the company.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Mr. Mateo positively, given his extensive industry experience.
• The appointment is not expected to have a direct impact on employees, customers, or suppliers.

Next Steps

• Mr. Mateo will begin his service on the Board of Directors immediately.
• The one-time grant of restricted stock units will be issued on July 31, 2024.
• Mr. Mateo will be eligible for additional cash retainers if he serves on board committees.

Key Dates

Keywords

Board of Directors, Alan V. Mateo, 10x Genomics, Life Sciences, Executive Appointment, Corporate Governance, Stock Options, Compensation